{
    "5e2b109cfbd6abf43b000002": "Length of stay, Acuity of admission",
    "5e2f906ffbd6abf43b00002c": "ibuprofen",
    "5e48136dd14c9f295d000008": "embryonic fibroblasts",
    "5e482160d14c9f295d00000c": "antioxidant activity",
    "5c72c9207c78d6947100007b": "microarray",
    "5e369ecfb5b409ea53000002": "Transcribed ultraconserved regions",
    "5e36ad01b5b409ea53000006": "transcribed ultraconserved regions",
    "5e46e8c13f5415952900000c": "pyrimidine dimers",
    "5cd96eb2a49efeb44c000003": "CNN-IndRNN",
    "5c70273c7c78d69471000061": "systemic lupus erythematosus",
    "5c7a4ed5d774d04240000008": "minimally invasive",
    "5c7006037c78d6947100005d": "amyloid A",
    "5c74305d7c78d694710000a4": "RIN/G3BPs",
    "5c7a4a31d774d04240000006": "limitations in sensitivity and reproducibility",
    "5e360f3d158f994d3a000009": "constipation",
    "5e493bc06d0a277941000003": "lung cancer",
    "5e2f43bafbd6abf43b000029": "severe acute respiratory syndrome",
    "5e5cbf4e1af46fc130000004": "amino acids and their analogs",
    "5e48100bd14c9f295d000007": "thyroid",
    "5cf0f567a49efeb44c00000b": "MBF",
    "5e30ee25fbd6abf43b00003f": "multiple Allergies",
    "5e46f9683f54159529000010": "reducing side effects",
    "5e4027f948dab47f2600000d": "meningitis",
    "5e5015436d0a277941000037": "MobiDB",
    "5e4f0a4f6d0a277941000031": "immunoglobulin heavy chain gene",
    "5e55046fb761aafe09000004": "fezolinetant",
    "5e494b0e6d0a277941000007": "six",
    "5e4be9496d0a27794100002a": "TKIs",
    "5d36a9507bc3fee31f000005": "human T\u00a0cells",
    "5e30f8abfbd6abf43b000047": "FMS-like tyrosine kinase 3",
    "5e4163b848dab47f2600000f": "influenza",
    "5e342175fbd6abf43b000064": "anorectal anomalies",
    "5e36a901b5b409ea53000005": "transcribed ultraconserved region",
    "5e3a6a4eb5b409ea53000016": "facial weakness",
    "5e475d3035b8f0833c000002": "clinical factors",
    "5e493a3e6d0a277941000002": "NBL2 transcript (TNBL",
    "5e6e4a6c51b80c9423000002": "Wdr5",
    "5e6e5d1d51b80c9423000003": "Schizophrenia",
    "5e44baaa48dab47f2600001a": "PI3K/AKT",
    "5e35c75d158f994d3a000001": "Treat to target",
    "5e3e8b1c48dab47f26000008": "promoted",
    "5e47546d3f54159529000019": "ulcerative colitis",
    "5e80669e835f4e4777000025": "angiotensin-converting enzyme 2",
    "5d387360a1e1595105000007": "apoptosis",
    "5e4949d36d0a277941000006": "ciliopathies",
    "5e3c841148dab47f26000002": "Alzheimer's disease",
    "5e4703d13f54159529000016": "chitosan-based long-circulating nanocarriers",
    "5e52c5166d0a27794100004d": "early stages",
    "5e6e8897c6a8763d23000003": "AZD5991, S64315",
    "5e7659db835f4e4777000001": "oral poliovirus vaccine",
    "5e80e449835f4e477700002c": "gallbladder",
    "5e7768f9835f4e477700000b": "Afrezza"
}
